Details

NameSymbolSector
BAL PHARMA LIMITEDBALPHARMAPharmaceuticals
Open
84.89
High
84.89
Low
83
Close
83.49
Volume
12585
Exchange
nse
Time
03-Oct-2025

Outlook

Score:  

1.5

Rating:  

RISKY

Candlestick Pattern

Candle pattern of Bal Pharma is  
None
Estimated Stoploss of Bal Pharma is ₹  
84.89
Bal Pharma has a  
Bearishℹ
 pattern. 
Formation of  
None
 candle pattern indicates the trend direction of Bal Pharma is  
Unpredictableℹ
. 

Trend

Bal Pharma is in  
Sideways trendℹ
. 
Price of Bal Pharma is  
Downℹ
 by  

5.72

%. 
Target
Buy @ 

80.29

Sell @ 

102.79

Current @ 

83.49

Volume

The trade volumes of Bal Pharma have become  
Deficientℹ
The volume trend for Bal Pharma is  
Bearishℹ
, but the participants are  
Weak Sellersℹ
The trade volume of Bal Pharma is  

Down

 by  

38.94

% 

Valuation

The current market price of Bal Pharma is  
Undervaluedℹ

Financials

Balance
With total liablities and shareholder equity worth ₹ 335cr and total assets worth ₹ 335cr, the balance sheet of Bal Pharma is:  
Balancedℹ
. 
Cashflow
Bal Pharma has  
Poorℹ
 cash flow because there is  

Shortage

 of  

₹ 2cr

. It is  
Downℹ
 by  

200

%. 

(*Mar 2025)

48.78% i.e. ₹ 20cr earned in operatingℹ
34.15% i.e. ₹ 14cr spent in investingℹ
17.07% i.e. ₹ 7cr spent in financingℹ
0% in otherℹ
Bal Pharma has  
Sufficientℹ
 cash flow because there is  

Surplus

 of  

₹ 2cr

. It is  
Upℹ
 by  

0

%. 

(*Mar 2024)

53.66% i.e. ₹ 22cr earned in operatingℹ
43.9% i.e. ₹ 18cr spent in investingℹ
2.44% i.e. ₹ 1cr spent in financingℹ
0% in otherℹ
Income
The income of Bal Pharma is  

₹ 66cr

 and  

Loss

 is :  

₹ 0cr

(*Jun 2025)

Bal Pharma Losses increased by:  

100

% and Income is Down by:  

19.51

% 

(*Jun 2025)

The income of Bal Pharma is  

₹ 82cr

 and  

Profit

 is :  

₹ 5cr

(*Mar 2025)

Bal Pharma Profit is up by:  

500

% and Income is Up by:  

12.33

% 

(*Mar 2025)

The income of Bal Pharma is  

₹ 73cr

 and  

Loss

 is :  

₹ 0cr

(*Dec 2024)

Bal Pharma Losses increased by:  

100

% and Income is Up by:  

0

% 

(*Dec 2024)

By using this site you agree to the use of cookies to deliver a better site experience.